X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Envelta (MET-LENK) is a non-addictive intranasal molecular envelope endogenous enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer.
Lead Product(s): Enkephalin
Therapeutic Area: Neurology Product Name: Envelta
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
Envelta™ is an intranasal molecular envelope endogenous enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer.
Lead Product(s): Enkephalin
Therapeutic Area: Neurology Product Name: Envelta
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
Envelta is an investigational intranasal formulation intended to improve enkephalin transport to the brain. Envelta uses a preassembled device and cartridge to propel the enkephalin formulation through the nose to the brain by flowing along the olfactory nerve pathway.
Lead Product(s): Enkephalin
Therapeutic Area: Neurology Product Name: Envelta
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2022
Details:
The NIH has contracted with a clinical research organization to conduct additional pre-clinical efficacy studies for Envelta and procured a device to be used with the manufactured GMP drug product for preclinical and clinical studies.
Lead Product(s): Enkephalin
Therapeutic Area: Oncology Product Name: Envelta
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 10, 2021
Details:
Under terms of the new contract, the company will support CMC's of NES-100, a microparticle dosage form of leu-enkephalin (LENK) that is prepared by the encapsulation of LENK in a patent-protected molecular enveloped technology and delivered via a nasal spray device.
Lead Product(s): Enkephalin
Therapeutic Area: Neurology Product Name: NES-100
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding October 20, 2021
Details:
Envelta™ is an investigational intranasal formulation intended to improve enkephalin transport to the brain. Enkephalin is a naturally occurring (endogenous) peptide that is not easily administered in its original form.
Lead Product(s): Enkephalin
Therapeutic Area: Oncology Product Name: Envelta
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: National Center for Advancing Translational Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 21, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
